Galderma has secured EU regulatory approval for Restylane Shaype, expanding its filler portfolio in a market where product differentiation increasingly hinges on rheology and longevity claims. Shaype enters a crowded midface and lip space already occupied by Restylane Lyft, Volbella, and Defyne, as well as Galderma's own Emervel line and competitors' offerings from Allergan and Revance.
Injectables
Galderma Wins EU Nod for Restylane Shaype
Galderma's newest filler gets European green light. What it means for your market positioning.
1-YEAR MOVE
ABBV
▲11.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
Galderma expands filler portfolio with EU approval for Restylane Shaype.
The timing matters: European practices have shown strong uptake of newer-generation fillers marketed on specific anatomical targeting and reduced migration risk. Shaype's EU clearance signals Galderma's confidence in the product's clinical profile and sets the stage for potential FDA submission in the U.S., where filler market share remains fiercely contested. Practices should monitor pricing and rebate positioning as Galderma rolls out the product—loyalty program incentives will likely determine adoption velocity in your region.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.